Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Australia Plans Accelerated Approvals

TGA Proposes Fee Waivers And Faster Generic Registrations To Tackle Shortages

Executive Summary

Australia’s Therapeutic Goods Administration has proposed a range of mechanisms to reduce regulatory burden on companies with the explicit aim of addressing medicines shortages.

You may also be interested in...



Lupin Acquires Australia’s Southern Cross

Lupin has broadened its reach in Australia after agreeing a deal to buy local generics developer and distributor Southern Cross.

Global Medtech Guidance Tracker: September 2022

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Forty-two documents have been posted on the tracker since its last update.

€5m Initiative To Help EU Member States Cooperate On Trial Safety Assessments

An EU funded project is to help national competent authorities cooperate on the safety assessment of clinical trials as required under the Clinical Trial Regulation.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB150793

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel